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Sudden cardiac death (SCD) in an athlete is a rare yet highly visible tragedy that generates significant media
attention and discussion among medical personnel, sports communities, and laypersons alike. The incidence of
SCD is greater in athletes compared with their nonathletic counterparts due to the increased risk associated
with strenuous exercise in the context of a quiescent cardiac abnormality. Numerous structural, electrical, and
acquired cardiovascular abnormalities are capable of causing SCD, many of which can be identified during life
and managed by lifestyle modifications, pharmacotherapy, and device therapy. Strategies for the prevention of
SCD, including pre-participation cardiovascular screening, are endorsed by sports governing bodies, but manda-
tory pre-participation cardiovascular screening remains rare. Evaluation of athletes poses diagnostic difficulties,
particularly differentiating between physiological adaptation to exercise, known as athlete’s heart, and cardio-
myopathic processes capable of causing SCD. This paper provides a detailed review regarding the etiology of
SCD in young athletes and provides insight into the challenges and dilemmas faced when evaluating ath-
letes for underlying pathological conditions. (J Am Coll Cardiol 2013;61:1027–40) © 2013 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1032The beneficial effects of regular exercise for primary and
secondary prevention of cardiovascular disease are well
documented (1). Paradoxically, athletes harboring quiescent
cardiovascular abnormalities are at greater risk of exercise-
related sudden cardiac death (SCD). Data from Italy have
shown a 2.8-fold greater risk of SCD among competitive
athletes compared with their nonathletic counterparts. SCD
results from intense physical exercise in the context of an
underlying cardiovascular abnormality (2). The mechanism
is typically ventricular arrhythmia, probably due to exercise-
induced catecholamine surges acting on an arrhythmogenic
substrate. Postulated contributory mechanisms also include
dehydration, hyperpyrexia, electrolyte imbalances, and in-
creased platelet aggregation associated with exercise (3).
The precise definition of an athlete is complex; however,
for the purposes of this review, we define an athlete as an
individual engaged in regular physical training and partici-
pating in official sports competition with an emphasis on
excellence and achievement (4). SCD in a young athlete is
often difficult for the public to comprehend because athletes
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accepted August 13, 2012.are perceived as the healthiest segment of society. Most
nontraumatic deaths are attributed to cardiovascular abnor-
malities that can be identified during life and managed with
lifestyle modifications including abstinence from exercise of
high or moderate intensity, pharmacotherapy, and implant-
able cardioverter-defibrillators (ICDs) (5). Prevention of
such catastrophes by pre-participation cardiovascular screening
(PPS) is recommended by learned organizations and sports
governing bodies including the European Society of Cardi-
ology (ESC), American Heart Association, and the Inter-
national Olympic Committee (6–8).
This paper provides a detailed review regarding the
etiology of SCD in young athletes and provides insight into
the challenges and dilemmas faced when evaluating athletes
for underlying pathological conditions.
Epidemiology of SCD in Athletes
The incidence of SCD among young athletes is a source of
debate, particularly as studies differ in their methodology.
Data compiled retrospectively from media reports, insur-
ance claims, and electronic databases are likely to represent
a significant underestimate. The most robust data are
derived from prospective, observational studies in Italy using
regional registry data with mandatory reporting systems,
which report incidence rates of 3.6/100,000 per year in the
pre-screening era. More recent cross-sectional studies from
the United States have demonstrated relatively similar
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ing from 2.3 to 4.4/100,000 per
year (9–11).
There is a significant male
predominance of SCD among
athletes. Data from the National
Center for Catastrophic Sports
Injury Research on high school
and college athletes reported a
5-fold higher incidence of SCD
in male compared with female
athletes (12). In the Veneto re-
gion of northern Italy, where
110,000 athletes were evalu-
ated over a 21-year follow-up
period, the incidence rates of
SCD were 2.6/100,000 person-
years in male athletes and 1.1/
100,000 person-years in their fe-
male counterparts (2). Several
factors are implicated in this sex
difference including lower partic-
ipation rates among female ath-
letes at the elite level, although
this trend is changing, and lower
prevalence of cardiac abnormali-
ties capable of causing SCD in
females (13).
Over the past 3 decades, there has
been an explosion in the number of
African/Afro-Caribbean (black)
athletes competing at the elite level
(14). SCD appears to be more com-
mon in this ethnic group, with a
reported incidence rate of 5.6/100,000 per year in the United
States (11). Cardiomyopathy has been consistently demonstrated
as the most common cause of exercise-related SCD in young
athletes. Data from U.S. autopsy series have reported higher death
rates from hypertrophic cardiomyopathy (HCM) in black com-
pared with white athletes (20% vs. 10%, respectively), raising
concern that this condition may exhibit a more malignant phe-
notype in black individuals (15).
Sudden death occurs more frequently in certain sports. In
the United States, basketball and football have the greatest
incidence, whereas in Europe, soccer predominates (16).
Extrapolation of this observation suggests that individuals
participating in sports of high dynamic and low isometric
intensity are at higher risk of death. However, there is the
potential for data bias due to higher participation rates in
these sports.
Etiology of SCD in Athletes
In athletes older than 35 years of age, 80% of SCD is
Abbreviations
and Acronyms
ARVC  arrhythmogenic
right ventricular
cardiomyopathy
BrS  Brugada syndrome
CCAA  congenital
coronary artery anomaly
ECG  electrocardiography
ER  early repolarization
ESC  European Society of
Cardiology
HCM  hypertrophic
cardiomyopathy
ICD  implantable
cardioverter-defibrillator
LQTS  long QT syndrome
LV  left ventricular
LVH  left ventricular
hypertrophy
LVWT  left ventricular
wall thickness
MVP  mitral valve
prolapse
PPS  pre-participation
screening
RV  right ventricular
SCD  sudden cardiac
death
VF  ventricular fibrillation
VT  ventricular
tachycardiafrequently due to atherosclerotic coronary artery disease, butin younger athletes, inherited and other acquired cardiovas-
cular abnormalities are usually responsible (Fig. 1). Cardio-
myopathy, including HCM and arrhythmogenic right ven-
tricular cardiomyopathy (ARVC), is the most common
cause of exercise-related SCD (5).
Structural cardiac abnormalities. HYPERTROPHIC CARDIO-
MYOPATHY. The reported prevalence of HCM is 0.2% in
he general population and 0.07% to 0.08% in athletes (17).
CM is a primary myocardial disorder with an autosomal
ominant pattern of inheritance, characterized by left ven-
ricular hypertrophy (LVH) in the absence of abnormal
oading conditions and myocardial disarray on histology.
udden death due to ventricular tachycardia (VT)/
entricular fibrillation (VF) is often the first clinical mani-
estation (18). Deaths caused by HCM are common in
tart-stop sports, for example, football and basketball, but
are in endurance events such as rowing, long-distance
ycling, and running. It is hypothesized that the combina-
ion of myocardial hypertrophy, impaired myocardial relax-
tion, myocardial ischemia, and dynamic left ventricular
LV) outflow obstruction impede augmentation of stroke
olume for prolonged periods, and individuals with HCM
re therefore usually selected out of endurance sports.
The diagnosis is made using electrocardiography (ECG)
nd echocardiography. More than 90% of affected individ-
als have an abnormal resting electrocardiogram (Figs. 2A
nd 2C) (19). All individuals with previous cardiac arrest or
ustained VT are at high risk of SCD and require treatment
ith an ICD. Other recognized risk factors for SCD
nclude: 1) unheralded syncope; 2) family history of SCD; 3)
evere LVH (30 mm); 4) sustained or nonsustained VT;
nd 5) attenuated blood pressure response to exercise. These
risk factors have low positive predictive value but high
egative predictive value. Subjects exhibiting 1 of the 5
isk markers should be considered for prophylactic insertion
f an ICD (20).
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY.
ARVC has a reported prevalence of 1/1,000 in the general
population. It is an inherited myocardial disease caused by
mutations in genes encoding cardiac desmosomal proteins
(21). The mechanism of SCD is complex and myocardial
stretch and myocyte detachment during exercise are thought
to result in ventricular arrhythmia and SCD. In survivors,
focal myocarditis with subsequent healing leads to progres-
sive fibrofatty replacement of the myocardium and a pro-
pensity to VT/VF. Macroscopic appearances include right
ventricular (RV) dilation, dysfunction, and aneurysm for-
mation (22). Exercise exacerbates these pathophysiological
changes, and a 5-fold higher risk of SCD in ARVC has
been demonstrated during competitive sports compared
with sedentary activity (2). Diagnosis relies on meeting the
2010 ARVC Task Force criteria, which include symptoms,
family history, resting/ambulatory electrocardiographic changes,
echocardiographic and cardiac magnetic resonance imaging
and myocardial tissue characterization (Figs. 2B and 2D)
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hemodynamic compromise and extensive structural disease
including LV involvement are risk factors for SCD and
should prompt consideration of prophylactic ICD implan-
tation (20,24).
CONGENITAL CORONARY ARTERY ANOMALIES. Congenital
coronary artery anomalies (CCAAs) reportedly cause SCD
in 12% to 33% of athletes. The most common anomalies
implicated are left coronary artery origins in the right sinus
of Valsalva and right coronary artery origins in the left sinus
of Valsalva (25). SCD results from ventricular arrhythmia
triggered by myocardial ischemia during exercise. Coronary
blood flow is impaired by the abnormal ostium of the
anomalous vessel, compression of the anomalous artery as it
courses between the pulmonary artery and ascending aorta,
and/or coronary spasm triggered by endothelial dysfunction
(26). Victims of SCD due to CCAA are often asymptom-
atic before presentation, although chest pain associated with
syncope should raise suspicion of the disorder.
Diagnosis using ECG, echocardiography, and exercise
stress testing is notoriously difficult because affected indi-
viduals rarely reveal features of inducible ischemia during
exercise stress testing or pharmacological functional tests.
Figure 1 Common Causes of Sudden Cardiac Death in Young A
The common causes of SCD in young athletes 35 years old can be divided intoCardiac magnetic resonance angiography and computed mtomography coronary angiography are the gold standard
imaging modalities (27). The usual recommended therapy
for CCAA is surgical correction; however, there is contro-
versy regarding which specific types of CCAA require surgical
correction in an asymptomatic athlete. Although surgery is
almost universally recommended for left-sided CCAA, clinical
management of a right-sided CCAA is more uncertain. It has
been suggested that an intramural course, acute-angled take
off, stenosis, or slitlike opening carry higher risk (25).
OTHER STRUCTURAL CARDIAC ABNORMALITIES. Other struc-
ural cardiac abnormalities associated with SCD include
ortic dissection/rupture typically in the context of Marfan
yndrome, mitral valve prolapse (MVP), and aortic stenosis.
arfan syndrome is a collagen disorder caused by mutations
n the gene encoding fibrillin, inherited as an autosomal
ominant trait with a prevalence of 1 in 5,000. It accounts
or approximately 3% of exercise-related SCD in young
thletes and is characterized by skeletal, cardiac, and ocular
bnormalities. Cystic medial necrosis in the tunica media of the
orta results in aortic dilation, dissection, or rupture, which
ay be expedited by the increases in aortic pressure
ssociated with exercise (28,29). Marfan patients should
e prohibited from isometric or isotonic exercise of
es
ral, electrical, and acquired cardiac abnormalities (22).thlet
structuoderate to high intensity. Individuals with an enlarged
he
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elp retard aortic dilation (30).
MVP affects 3% to 5% of the general population; how-
ver,100 cases of SCD have been reported in which MVP
was the only abnormality identified, and only 3 occurred
during physical exertion. Most individuals are asymptom-
atic. In rare instances, the condition is associated with VT,
although the exact mechanism is unknown. The relatively
high-frequency of MVP in the general population raises the
question of whether identification of MVP in a victim of
SCD is causal or coincidental (31,32). In general, athletes
with MVP are allowed to continue to compete; however,
competitive sport is precluded when MVP is associated with
moderate to severe mitral regurgitation, severe chest pain,
exertional syncope, documentation of VT, a long QT
interval, or Marfan syndrome (30).
Aortic stenosis due to a congenital bicuspid aortic valve is
a rare but recognized cause of SCD in young athletes that
can be identified through basic screening efforts involving
cardiovascular physical examination. Athletes with mild
aortic stenosis may compete in low- to moderate-intensity
Figure 2 ECG and Imaging Abnormalities Observed in HCM and
(A) Electrocardiogram (ECG) in hypertrophic cardiomyopathy (HCM) demonstrating
trophy. There is ST-segment depression with deep T-wave inversion in leads I, aVL
genic right ventricular cardiomyopathy (ARVC) demonstrating T-wave inversion in rig
significant asymmetrical septal hypertrophy (arrow) measuring 22 mm. (D) Cardia
fibrosis.dynamic or static sports provided that they are asymptomaticand free of documented arrhythmia, with normal LV function
both at rest and during exercise echocardiography (30).
Electrical cardiac abnormalities. WOLFF-PARKINSON-
WHITE SYNDROME. Wolff-Parkinson-White syndrome de-
scribes ventricular pre-excitation due to anterograde con-
duction via an accessory atrioventricular pathway with
paroxysmal arrhythmias that usually result from atrioven-
tricular re-entrant tachycardia (33). The prevalence of pre-
excitation in athletes is similar to that in the general
population (0.1% to 0.3%) and may be revealed by a delta
wave, short PR interval, and prolonged QRS duration on
the electrocardiogram (Fig. 3A). Most affected athletes are
asymptomatic, but some report symptoms of palpitations. If
atrial fibrillation develops in individuals with Wolff-
Parkinson-White syndrome, there is a risk of SCD from VF
secondary to rapid anterograde conduction via the accessory
pathway (34). Determining the electrical properties of the
accessory pathway is therefore crucial for establishing the
risk of SCD. Curative catheter ablation of the accessory
pathway in adults permits return to competitive sport
after 3 months (33). Recent guidance suggests that in
C
is deviation, voltage criteria for left atrial enlargement, and left ventricular hyper-
V5 and V6, and T-wave inversion in leads II and V3 and V4. (B) ECG in arrhythmo-
cordial leads. (C) Transthoracic echocardiogram demonstrating HCM with
netic resonance scan showing ARVC with right ventricular (RV) dilation and wallARV
left ax
, and
ht pre
c magadolescents, only high-risk pathways require catheter
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recommended (35).
CONGENITAL LONG QT SYNDROMES. Long QT syndrome
LQTS) comprises a group of hereditary ion channelopa-
hies with a prevalence of 1 in 2,000 to 5,000 in the general
opulation. The incidence of SCD in athletes due to LQTS
as 2% in the U.S. registry data (15). Although 12 different
ulpable genes have been identified, 70% of cases are due
o loss-of-function mutations in KCNQ1 (encoding potas-
ium channel IKs; LQT1) and KCNH2 (encoding potassium
Figure 3 Electrocardiographic Patterns Observed in Electrical C
(A) Wolff-Parkinson-White syndrome with characteristic short PR interval, delta wav
V4. (B) Congenital long QT syndrome with QTc interval of 460 ms. (C) Brugada s
leads V1 through V4 (type 1 electrocardiographic pattern).hannel IKr; LQT2) and gain-of-function mutations inSCN5A (encoding sodium channel INa; LQT3). Abnormal
cardiac repolarization predisposes to polymorphic VT/VF.
Individuals present with pre-syncope, syncope, palpita-
tions, or SCD. LQTS may be misdiagnosed as epilepsy
due to myoclonic movements occurring during syncope.
LQT1 is most commonly associated with SCD during
exercise, in particular, swimming and diving, likely due to
adrenergic surges that occur with sudden immersion in
cold water (36).
LQTS should be considered when the QTc interval
c Abnormalities Associated With Sudden Cardiac Death
longed QRS interval, and ST-segment depression in leads I, aVL, and V2 through
me with characteristic coved-type and down-sloping ST-segment elevation inardia
e, pro
yndroexceeds 440 ms in males or 460 ms in females, in the
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interval prolongation (37). Athletes may exhibit slightly
longer QT intervals compared with the general population
and 0.4% to 0.7% of highly trained athletes may exhibit
values 440 to 460 ms (see the following text). The 36th
Bethesda Conference guidelines therefore recommend re-
striction of athletic individuals with a QTc interval exceed-
ing 470 ms in males and 480 ms in females to improve the
positive predictive value (29). The diagnosis of LQTS
should be made using probability scoring systems that
include symptoms, family history, electrocardiographic
changes (Fig. 3B) and evidence of torsade de pointes, as
some affected individuals have a QTc interval within the
normal range (38). High-risk features include a QTc inter-
val 500 ms and adolescents or females with the LQT2
genotype. Individuals with a history of aborted SCD,
recurrent syncope, and polymorphic VT despite medical
therapy with beta-blockers should be considered for pro-
phylactic implantation of an ICD (39).
BRUGADA SYNDROME. Brugada syndrome (BrS) is an au-
tosomal dominant sodium channelopathy with an incidence
of 1 in 2,000 to 5,000 (40). The condition is characterized
by a partial right bundle branch block pattern on the
electrocardiogram with associated coved ST-segment eleva-
tion (BrS type 1 electrocardiographic pattern) (Fig. 3C).
Individuals present with syncope or SCD due to polymor-
phic VT/VF. Mixed phenotypic expressions of the disease,
ranging from distinct repolarization abnormalities to sub-
clinical cardiac conduction defects, also occur. BrS is not
typically associated with exercise-related SCD; however,
increased vagal tone induced by chronic athletic condition-
ing at rest and exercise-induced hyperthermia may enhance
the propensity to SCD and may trigger ventricular arrhyth-
mias (41). The only established treatment is ICD insertion.
Although deaths from BrS characteristically occur at rest,
intensive exercise is generally not advised because it may be
associated with profound bradycardia and core temperatures
exceeding 40°C, both of which may precipitate fatal ar-
rhythmias in affected individuals.
CATECHOLAMINERGIC POLYMORPHIC VT. Catecholamin-
ergic polymorphic VT is associated with mutations in the
ryanodine receptor, calsequestrin, and ankyrin-B proteins,
which predispose to adrenergically mediated polymorphic
VT and recurrent syncope provoked by physical exercise or
emotional stress (42). Typically, the baseline electrocardio-
gram is unremarkable, but exercise stress testing may pro-
voke multifocal ventricular premature beats or VT with beat
to beat 180° alternating QRS axis (bidirectional VT). The
disorder commonly presents in adolescence, and affected
individuals may have a family history of juvenile sudden
death or stress-induced syncope. Prevention of SCD in-
cludes medical therapy with beta-blockers and ICD inser-
tion in those who continue to experience symptoms despite
medical therapy.Acquired cardiac abnormalities. COMMOTIO CORDIS.
Blunt trauma to the chest can trigger VF and SCD without
causing direct injury to the thoracic cage or heart (43).
Commotio cordis typically occurs in sports with projectile
objects such as ice hockey, lacrosse, and baseball. High-risk
contact sports such as martial arts and player collisions in
team sports such as soccer have also been implicated.
Commotio cordis is more common in children and adoles-
cents due to a thin and compliant thoracic cage that allows
greater transmission of energy to the heart. In animal
models, a single blow directly over the precordium 10 to 30
ms before the T-wave peak on the electrocardiogram has been
demonstrated to induce VF. A rapid increase in LV pressure
follows, which appears to activate ion channels via mechano-
electric coupling, resulting in the generation of an inward
current, augmentation of repolarization, and nonuniform myo-
cardial activation. Subsequent premature ventricular depolar-
izations trigger VF and SCD (44).
MYOCARDITIS. Myocarditis, typically caused by viral infec-
ions (e.g., Coxsackie B) accounts for up to 7% of SCD in
thletes (45). The diagnosis of myocarditis should be
onsidered in any healthy young individual with recent viral
llness, new exercise intolerance, clinical signs of cardiac
ailure, electrocardiographic repolarization abnormalities,
nd/or echocardiographic regional wall motion abnormali-
ies. Active myocarditis can be identified on cardiac mag-
etic resonance imaging. Acute illness is associated with
entricular arrhythmia. In some cases, myocarditis can lead
o a dilated cardiomyopathy with ongoing symptoms of
ardiac dysfunction and increased risk of SCD (46). Ath-
etes diagnosed with myocarditis should refrain from sports
ctivity for a 6-month convalescent period to reduce the risk
f SCD.
P E R F O R M A N C E - E N H A N C I N G D R U G S . The use of
erformance-enhancing drugs occurs in athletes, although
he true incidence is unknown. Anabolic-androgenic ste-
oids, stimulants such as ephedrine, and nonsteroidal agents
uch as recombinant human erythropoietin have been asso-
iated with SCD, but a causal relationship is difficult to
scertain given that their use is forbidden. Anabolic andro-
enic steroids have been shown to change lipoprotein
etabolism leading to premature atherosclerosis and myo-
ardial infarction. These agents also induce hypertension
nd both anabolic-androgenic steroid and ephedrine use
ay result in cardiomyopathy and ventricular arrhythmias.
oxicological investigation is therefore recommended after
SCD event in an athlete (47).
PREMATURE CORONARY ARTERY DISEASE. In large series
from Italy and the United States, premature atherosclerotic
coronary artery disease accounted for 2% to 3% of SCD in
young athletes (9,15). It is most commonly a manifestation
of familial hypercholesterolemia. Symptoms are rare, and
SCD is often the first presentation; however, peripheral
UE
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March 12, 2013:1027–40 Sudden Cardiac Death in Young Athletesstigmata including xanthelesma, corneal arcus, and xantho-
mata are more common and should raise suspicion.
Recommendations for competitive sports participation by
athletes diagnosed with potential causes of SCD exist in the
nited States and Europe and are summarized in Table 1 (4,29).
Evaluation of Athletes and Diagnostic Dilemmas
PPS is supported by sports organizations at the interna-
tional and national levels (6). However, a potential limita-
tion is the need for highly trained medical personnel with
experience evaluating athletes, interpreting their clinical
data, and organizing relevant further investigations when
required without affecting training regimens and sporting
events. An algorithm for the assessment of athletes for
conditions capable of causing SCD is presented in Figure 4.
Diagnostic Dilemmas
Athlete’s heart. Regular physical exercise can lead to phys-
iological adaptation in cardiac dimensions, including in-
Recommendations for Competitive Sports Participation Among AthTable 1 Recommendations for Competitive Sports Participation
Condition 36th Bethesda Conference
Structural cardiac abnormalities
HCM Exclude athletes with a probable or definitive clin
all competitive sports.
Genotype-positive/phenotype-negative athletes m
ARVC Exclude athletes with a probable or definitive dia
competitive sports.
CCAA Exclude from competitive sports.
Participation in all sports 3 months after success
be permitted for an athlete with ischemia, ven
or tachyarrhythmia, or LV dysfunction during m
testing.
Electrical cardiac abnormalities
WPW Athletes without structural heart disease, without
palpitations, or without tachycardia can partic
competitive sports.
In athletes with symptoms, electrophysiological s
are recommended. Return to competitive spor
corrective ablation, provided that the ECG has
LQTS Exclude any athlete with a previous cardiac arres
episode from competitive sports.
Asymptomatic patients restricted to competitive
Genotype-positive/phenotype-negative athletes m
BrS Exclude from all competitive sports except those
CPVT Exclude all patients with a clinical diagnosis from
Genotype-positive/phenotype-negative patients m
low-intensity sports.
Acquired cardiac abnormalities
Commotio cordis Eligibility for returning to competitive sport in sur
individual clinical judgment. Survivors must un
cardiovascular workup including 12-lead elect
ambulatory Holter monitoring, and echocardio
Myocarditis Exclude from all competitive sports.
Convalescent period of 6 months.
Athletes may return to competition when test resARVC  arrhythmogenic right ventricular cardiomyopathy; BrS  Brugada syndrome; CCAA  congenita
CG  electrocardiogram; HCM  hypertrophic cardiomyopathy; LQTS  long QT syndrome; LV  left vecreased LV wall thickness (LVWT) and LV cavity size,
which may be reflected on ECG and echocardiography (48).
Such remodeling, termed athlete’s heart, permits en-
hanced filling of the left ventricle in diastole and aug-
mentation of stroke volume allowing generation of a large
and sustained cardiac output even at rapid heart rates.
The magnitude to which this adaptation occurs is influ-
enced by several demographic factors including age, sex,
body surface area, sport undertaken, and ethnicity (3).
Consequently, a significant diagnostic dilemma can arise
when attempting to differentiate physiological adapta-
tion, with associated electrocardiographic and echocar-
diographic changes, from cardiac pathology. This is
particularly important because false-positive diagnoses
may lead to erroneous disqualification from a sport with
loss of earnings and significant psychological distress to
the athlete, whereas false-negative evaluations may result
in devastating SCD.
The ESC has devised recommendations for electrocar-
diographic interpretation in athletes, which have reduced
With Potential Causes of SCD (4,29)ng Athletes With Potential Causes of SCD (4,29)
European Society of Cardiology
agnosis from Exclude athletes with a probable or definitive clinical diagnosis
from all competitive sports.
l compete. Exclude genotype-positive/phenotype-negative individuals from
competitive sports.
from Exclude athletes with a probable or definitive diagnosis from
competitive sports.
Not applicable.
gery would
r arrhythmia
l exercise
ory of
all
Athletes without structural heart disease, without a history of
palpitations, or without tachycardia can participate in all
competitive sports.
nd ablation
llowed after
lized.
In athletes with symptoms, electrophysiological study and ablation
are recommended. Return to competitive sport is allowed after
corrective ablation, provided that the ECG has normalized.
ncopal Exclude any athlete with a clinical or genotype diagnosis from
competitive sports.
ensity sports.
l compete.
intensity. Exclude from all competitive sports.
etitive sports. Exclude all patients with a clinical diagnosis from competitive
sports.
l compete in Genotype-positive/phenotype-negative patients are also excluded.
is a matter of
a thorough
ography,
.
Not applicable.
Exclude from all competitive sports.
Convalescent period of 6 months.
rmalize. Athletes may return to competition when test results normalize.letesAmo
ical di
ay stil
gnosis
ful sur
tricula
axima
a hist
ipate in
tudy a
ts is a
norma
t or sy
low-int
ay stil
of low
comp
ay stil
vivors
dergo
rocardi
graphy
ults nol coronary artery anomalies; CPVT  cathecholaminergic polymorphic ventricular tachycardia;
ntricular; WPW  Wolff-Parkinson-White syndrome.
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Sudden Cardiac Death in Young Athletes March 12, 2013:1027–40false-positive rates, in Caucasian athletes at least. Group 1
changes result from physiological adaptation of the cardiac
autonomic nervous system and occur in as many as 80% of
athletes, but Group 2 changes occur in 5% and are
suggestive of underlying cardiovascular disorders, most no-
tably cardiomyopathy and ion channelopathy. When Group
2 electrocardiographic changes are observed, further cardiac
Figure 4 Algorithm for Evaluating Athletes for Conditions Capa
The evaluation of athletes for conditions predisposing to SCD must incorporate cli
with further investigations as required. CCAA  congenital coronary artery anomal
LQTS  long QT syndrome; LVH  left ventricular hypertrophy; MRI  magnetic re
WPW  Wolff-Parkinson-White syndrome.evaluation is recommended (Table 2) (37).Athlete’s heart versus HCM. A proportion of male ath-
letes, predominantly those involved in endurance sports,
demonstrate extreme physiological adaptation with LVWT
measurements of 13 to 15 mm (49). Although the majority
of individuals with HCM have a mean LVWT of 18 to
20 mm, 8% have morphologically mild hypertrophy.
Therefore, a male athlete with an LVWT of 13 to 15 mm
f Causing SCD
istory, physical examination, 12-lead ECG and trans-thoracic echocardiography
 dilated cardiomyopathy; LA  left atrium; LBBB  left bundle branch block;
ce imaging; RBBB  right bundle branch block; SCD  sudden cardiac death;ble o
nical h
y; DCM
sonanfalls into a ‘grey zone’, where differentiation between
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March 12, 2013:1027–40 Sudden Cardiac Death in Young Athletesphysiological LVH and HCM is crucial. This diagnostic
dilemma occurs in 2% to 4% of white male athletes and
12% to 18% black male athletes (Fig. 5) (50,51).
In the majority of athletes, differentiating physiology
from pathology is possible using ECG and echocardiogra-
phy. Isolated QRS voltage criteria for LVH are commonly
observed in athletes but occur in only 2% of individuals with
HCM. Electrocardiographic changes suggestive of HCM
include T-wave inversion, pathological Q waves, ST-
segment depression in 2 contiguous leads, and left bundle
European Society of CardiologyClassificati n of Abnormalities on theAthlete’s 12-L ad Elect ocardiogram (37)
Table 2
European Society f Cardiology
Classification of Abnormalities on the
Athlete’s 12-Lead Electrocardiogram (37)
Group 1: Common and
Training-Related
Electrocardiographic Changes
Group 2: Uncommon and
Training-Unrelated
Electrocardiographic Changes
Sinus bradycardia T-wave inversion
First-degree atrioventricular block ST-segment depression
Incomplete right bundle branch
block
Pathological Q waves
Early repolarization Left atrial enlargement
Isolated QRS voltage criteria for left
ventricular hypertrophy
Right atrial enlargement
Left axis deviation
Right axis deviation
Right ventricular hypertrophy
Ventricular pre-excitation
Left bundle branch block
Right bundle branch block
Long QTc interval (440 ms in males;
460 ms in females)
Short QTc interval (380 ms)
Brugada-like early repolarization
Figure 5 Differentiating Between Physiology and Pathology: ‘A
Regular exercise can lead to physiological adaptation of cardiac structure and func
phy. There is some overlap with HCM and ARVC (yellow arrows). Key features can
tal hypertrophy; CMR  cardiac magnetic resonance imaging; CPET  cardiopulmo
ventricular; VT  ventricular tachycardia; other abbreviations as in Figures 2 and 4branch block. Inverted T waves 1 mm in depth in 2
contiguous leads except V1 and V2 in white athletes and V1
through V4 in black athletes should raise suspicion for
CM (52). Physiological LVH is homogeneous and asso-
iated with chamber enlargement and normal indexes of
iastolic function. In contrast, individuals with HCM often
how asymmetrical patterns of LVH, small chamber size,
nd impaired diastolic function. End-diastolic LV dimen-
ions 55 mm are common in trained athletes but are rare
n HCM in which the LV cavity size is usually45 mm. In
ddition, HCM is associated with abnormal pulsed and
issue Doppler indexes of LV diastolic filling and impaired
elaxation. In selected athletes, cardiac magnetic resonance
maging may offer incremental diagnostic value for detec-
ion of segmental LVH in the anterolateral free wall,
osterior ventricular septum or apex, and demonstration of
elayed gadolinium enhancement indicative of myocardial
brosis (53). In equivocal cases, the presence of a family
istory of HCM or SCD and low peak oxygen consumption
peak VO2max 50 ml/kg/min) on cardiopulmonary exer-
cise testing favor a diagnosis of HCM. Genetic analysis has
a high positive predictive value but a low negative predictive
value and remains costly and time-consuming (54). In rare
cases, re-evaluation with ECG and echocardiography after a
period (8 to 12 weeks) of detraining may be the only
practical method of differentiating between the 2 entities.
Athlete’s heart versus ARVC. The diagnosis of ARVC in
athletes is particularly challenging. Early in the disease
process, the “concealed phase,” the heart may appear mor-
phologically normal (Fig. 5). Minor electrocardiographic
abnormalities in RV leads, infrequent ventricular extra
systoles of RV origin, and subtle changes in the right
’s Heart’ Versus HCM and ARVC
thlete’s heart) which can be identified by changes on ECG and echocardiogra-
ed to differentiate between physiology and pathology. ASH  asymmetrical sep-
xercise test; ETT  exercise tolerance test; LV  left ventricular; RV  rightthlete
tion (a
be us
nary e
.
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disorder, and these may overlap with physiological adapta-
tion of the right ventricle to regular exercise (22). The
presence of epsilon waves, abnormal late potentials on signal
averaged ECG, nonsustained VT of left bundle branch
block morphology, and RV regional wall motion abnormal-
ities favor the diagnosis of ARVC (55).
The majority of current data regarding RV size and
function are determined on the basis of dimensions derived
from small cohorts of normal individuals. Previous imaging
studies have demonstrated that athlete’s heart represents
balanced cardiac enlargement with proportional increases in
LV and RV mass, LV and RV end-diastolic volumes, and
LV and RV stroke volumes compared with sedentary
controls (56). The impact of exercise on the right ventricle
has not been studied as comprehensively as the left ventricle,
probably due to difficulties arising from its complex shape
and trabeculated structure. However, studies of endurance
athletes have shown that cardiac remodeling is not limited
to the left heart. Data from 102 subjects demonstrated
chronic RV cavity enlargement with RV outflow tract values
greater than the proposed major criteria for ARVC in 28%
of endurance athletes (23,57). As-yet unpublished data from
our group have demonstrated significantly increased echo-
cardiographic RV dimensions in professional soccer players,
greater than the upper reference limits defined by the ESC
and American Society of Echocardiography (58). This
increases the difficulty in differentiating between physiolog-
ical adaptation and ARVC, and larger studies are necessary
to determine physiological upper limits of RV dimensions in
athletes.
QTc interval in athletes. The diagnosis of congenital
LQTS is determined on the basis of a triad of a prolonged
QTc interval, unheralded syncope or documented polymor-
phic VT, and family history of SCD or LQTS. Although
the prevalence of LQTS is 1 in 2,500 to 10,000 in the
general population, in athletes, QTc interval prolongation is
reportedly as high as 0.4% to 0.7% (equivalent to 1 in 150
to 250) and therefore higher than the prevalence of cardio-
myopathy (59). Current data on SCD in young athletes
indicate that death due to ion channel disease occurs in 2%
to 4% of cases (15,16). The relatively high prevalence of
QTc interval prolongation in athletes and the low death rate
of LQTS suggest that the majority of causal mutations may
be relatively benign and/or that most athletes with an
isolated long QTc interval do not actually have LQTS.
Isolated QTc interval prolongation in an athlete may
represent delayed repolarization as a result of increased LV
mass, autonomic adaptation, or the fact that Bazett’s for-
mula undercorrects the QTc interval at low heart rates (59).
However, as many as 34% of SCDs in athletes from the
U.S. registry data remain unexplained and undiagnosed ion
channel disease may therefore also account for a proportion
of this group (15). Our own data, which was determined on
the basis of 118 consecutive SCD referred to a tertiary
cardiac pathology center, failed to identify an abnormality in23% of cases. However, it could be argued that the high
incidence of normal hearts may represent a referral bias
because deaths associated with structurally normal hearts
were more likely to be referred to a tertiary cardiac pathol-
ogy center for more detailed assessment (60).
Black athletes. Studies have demonstrated that black in-
dividuals exhibit more marked electrocardiographic repolar-
ization changes and a greater magnitude of LVH on
echocardiography compared with white individuals (14). It
can be extrapolated that exercise-associated increases in
preload and afterload may result in greater physiological
cardiac adaptation in black compared with white athletes,
leading to greater overlap with disease phenotypes, in
particular HCM.
Data from the United Kingdom have demonstrated
significantly greater LVH by voltage criteria (68% vs. 40%,
respectively; p  0.001), repolarization abnormalities in-
cluding ST-segment elevation (85% vs. 62%, respectively;
p  0.001), and deep T-wave inversion (12% vs. 0%,
espectively; p  0.001) in black athletes compared with
their white counterparts (51). T-wave inversion occurs
predominantly in electrocardiographic leads V1 through V4.
urther comprehensive clinical evaluation and follow-up
ata has shown no evidence of underlying cardiomyopathy
n black athletes with anterior T-wave inversion in leads V1
through V4, suggesting that this is likely to represent a
benign finding in this ethnic group (Figs. 6A and 6B).
Echocardiographic data from athletes matched for age,
body surface area, and sport showed significantly greater
LVWT in black than white athletes (11.3 mm vs. 10.0 mm,
respectively; p  0.001) (Fig. 6C) (51). Among black
athletes, 18% exhibited an LVWT13 mm, and 3% had an
LVWT 15 mm, in the range consistent with morpholog-
ically mild HCM. In contrast, only 4% of white athletes had
an LVWT 13 mm, and none had an LVWT 15 mm.
None of the black athletes with LVH exhibited other
phenotypic features of HCM on echocardiography, cardiac
magnetic resonance imaging, exercise stress testing, or 24-h
electrocardiographic monitoring. In black male athletes, an
LVWT 13 mm warrants further investigation but may
represent physiological adaptation, whereas an LVWT 16
mm is suggestive of underlying pathology. The greater
prevalence of repolarization changes on ECG and increased
LVWT on echocardiography have also been demonstrated
to a lesser extent in female (Fig. 6D) and adolescent black
athletes (61,62).
Early repolarization in athletes. Early repolarization (ER)
was historically considered a benign electrocardiographic
variant but has emerged as a risk marker for SCD. Inferior/
inferolateral ER with a horizontal/descending ST-segment
is associated with idiopathic VF in the general population
(63). The prevalence of ER is higher in athletes, ranging
from 22% to 43% and is more common in male black
athletes with lower heart rates and greater training duration
(64). It is typically observed in the lateral electrocardio-
graphic territory with rapidly up-sloping ST-segment mor-
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athletes is benign, although 1 study has shown an increased
prevalence of inferior/inferolateral ER with a horizontal/
descending ST-segment in athletic survivors of cardiac
arrest (65). At present, there is insufficient evidence to make
recommendations for competitive sports participation.
Primary and Secondary Prevention
of SCD in Athletes
Pre-participation cardiovascular screening. PPS of ath-
letes is recommended by both the American Heart Associ-
ation and ESC. In the United States, a 12-point screening
protocol encompassing symptoms, family history, and phys-
ical examination is recommended, whereas in Italy, a manda-
ory state-sponsored screening program incorporating 12-lead
CG, symptoms, family history, and physical examination
xists for all competitive athletes (5). The Italian PPS protocol
has been in place for 25 years, and on the basis of the data
generated from this experience, the ESC recommends PPS
including ECG in a consensus document endorsed by the
International Olympic Committee (6,37).
Incorporating ECG into a screening protocol improves
efficacy in identifying conditions capable of causing SCD. It
is the gold-standard investigation for detection of electrical
Figure 6 Patterns of Repolarization Changes and Distribution o
and Their White Counterparts
(A) Electrocardiogram (ECG) of a black male marathon runner demonstrating ST-se
physiological adaptation to exercise in this ethnic group. (B) ECG of a black male
ventricular hypertrophy and deep T-wave inversion in leads II, III, and aVF, suggest
millimeters) in black male and white male athletes demonstrating a significant pro
ble with morphologically mild hypertrophic cardiomyopathy (HCM). (D) Distribution
proportion of black female athletes with a maximal LVWT 12 mm, compatible wiabnormalities such as Wolff-Parkinson-White syndrome, sand ion channelopathies, including LQTS and BrS. ECG
is also effective in identifying cardiomyopathy, and its
findings are abnormal in 90% of individuals with HCM
and 75% of individuals with ARVC (18,66). The most
compelling evidence in support of the Italian PPS model
comes from a prospective study with 25 years of follow-up
that compared the incidence of SCD in the pre-screening
(1979 to 1982) and post-screening eras. This demonstrated
a significant reduction in the incidence of SCD from
3.6/100,000 person-years to 0.4/100,000 person-years (p 
.001), representing a 90% reduction in mortality (9). The
redominant reason for this reduction was decreased SCD
ue to cardiomyopathy, in particular, ARVC, which was a
elatively novel entity during the pre-screening era.
Despite such strong evidence for incorporating ECG in
PS, controversy remains, and the American Heart Asso-
iation does not support routine use of ECG. The primary
rguments against electrocardiographic screening include
oncerns regarding false-positive results, cost-effectiveness,
nd psychological implications for athletes and their families
5). Sudden death in the sports arena remains rare, and
CG cannot identify all conditions associated with SCD.
ue to overlap between the physiological electrocardio-
raphic changes seen in athlete’s heart and similar changes
T in Black Male and Female Athletes
t elevation in leads V1 through V3 with deep T-wave inversion consistent with
demonstrating ST-segment elevation in leads V1 through V4 but associated left
cardiac pathology. (C) Distribution of left ventricular wall thickness (LVWT) (in
n of black male athletes with a maximal LVWT between 13 and 16 mm, compati-
T in black female and white female athletes also demonstrating a significant
phologically mild HCM.f LVW
gmen
boxer
ive of
portio
of LVW
th moreen in pathological states, it is important that evaluation is
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cians with expertise and experience in dealing with athletes
and the complex phenotypic expressions of inherited cardiac
diseases. The diversity in age, sex, ethnicity, and sport
among the modern athletic population further complicates
matters, particularly as the majority of published data
originate from adult white males. Applying established
guidelines for electrocardiographic abnormalities to athletes
has been shown to generate false-positive rates between 4%
and 7%, which has important implications for both the
athlete and physician (67). However, the majority of SCD
occurs in individuals without antecedent symptoms and
with unremarkable cardiovascular examination, thus high-
lighting the advantages of evaluation incorporating ECG.
Studies comparing the cost-effectiveness of the U.S. and
Italian screening models find in favor of the Italian protocol
(68). However, the national screening program in Italy is
already well organized and established. It may not be
possible to reproduce these results in other countries with
limited infrastructure to run a nationwide screening pro-
gram and fewer trained medical personnel to implement it.
An important question is where the financial burden of
large-scale screening should fall; should it be paid for by
sporting bodies and teams or regional and national govern-
ments? There are limited data evaluating the psychological
implications of screening on athletes. A study of Norwegian
soccer players showed the majority of individuals were
satisfied having completed the screening and felt more
confident. Less than 3% were distressed by it, and all the
players involved would recommend screening to others (69).
Data from other established screening programs, including
prostate and breast cancer, demonstrate considerable anxiety
generated by false-positive results until further investiga-
tions provide reassurance, highlighting the importance of
prompt evaluation and referral to specialist centers (70).
With athletes, there are significant social and financial losses
to consider, as well as the long-term implications regarding
family screening and insurance policies.
Automated external defibrillators. In the event of cardiac
arrest in an athlete, survival is improved by prompt recog-
nition, the presence of trained medical personnel to initiate
cardiopulmonary resuscitation, and early access to an auto-
mated external defibrillator. Creation of emergency re-
sponse plans at sports and athletic venues may improve the
outcome of SCD events in athletes. A recent analysis of
1,710 U.S. high schools with on-site automated external
defibrillators reported 36 cases of cardiac arrest. Of the 36
cases of cardiac arrest, a total of 23 individuals (64%)
survived to hospital discharge, demonstrating that early
defibrillation provides a survival benefit to young athletic
victims of cardiac arrest (71).
Conclusions
SCD in the sports arena is rare but devastating. Preventive
strategies, such as large-scale PPS of competitive athletesand increasing availability of automated external defibrilla-
tors are challenges requiring significant infrastructure and
expertise but should be considered achievable aims rather than
impossible goals. Victims of SCD are often entirely asymp-
tomatic before their initial presentation and demonstrate only
subtle abnormalities on investigation. It is therefore recom-
mended that cardiac evaluation of an athlete is performed by
trained cardiologists and sports physicians familiar with the
conditions capable of causing SCD and the impact of demo-
graphic factors associated with the individual athlete.
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